Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

导出 OA

翻译打印收藏纠错

第一作者： Michael J,Haller

第一单位： University of Florida Diabetes Institute, Gainesville, FL hallemj@peds.ufl.edu.

作者： Michael J,Haller ^[1] ; S Alice,Long ^[2] ; J Lori,Blanchfield ^[2] ; Desmond A,Schatz ^[3] ; Jay S,Skyler ^[4] ; Jeffrey P,Krischer ^[5] ; Brian N,Bundy ^[5] ; Susan M,Geyer ^[5] ; Megan V,Warnock ^[5] ; Jessica L,Miller ^[5] ; Mark A,Atkinson ^[3] ; Dorothy J,Becker ^[4] ; David A,Baidal ^[6] ; Linda A,DiMeglio ^[4] ; Stephen E,Gitelman ^[7] ; Robin,Goland ^[8] ; Peter A,Gottlieb ^[9] ; Kevan C,Herold ^[10] ; Jennifer B,Marks ^[11] ; Antoinette,Moran ^[4] ; Henry,Rodriguez ^[12] ; William E,Russell ^[5] ; Darrell M,Wilson ^[13] ; Carla J,Greenbaum ^[14] ; Type 1 Diabetes TrialNet ATG-GCSF Study Group ^[2]

作者单位： University of Florida Diabetes Institute, Gainesville, FL hallemj@peds.ufl.edu. ^[1] Benaroya Research Institute, Seattle, WA. ^[2] University of Florida Diabetes Institute, Gainesville, FL. ^[3] Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL. ^[4] University of South Florida, Tampa, FL. ^[5] University of Pittsburgh, Pittsburgh, PA. ^[6] Indiana University, Indianapolis, IN. ^[7] University of California, San Francisco, San Francisco, CA. ^[8] Columbia University, New York, NY. ^[9] University of Colorado Barbara Davis Center for Childhood Diabetes, Aurora, CO. ^[10] Yale University, New Haven, CT. ^[11] University of Minnesota, Minneapolis, MN. ^[12] Vanderbilt University, Nashville, TN. ^[13] Stanford University, Stanford, CA. ^[14]